Cargando…
The role of adjuvant chemotherapy after neoadjuvant chemotherapy or chemoradiotherapy plus esophagectomy in patients with esophageal cancer: a retrospective cohort study
BACKGROUND: The 5-year survival rate of patients with locally advanced esophageal cancer is still low after neoadjuvant therapy plus esophagectomy, and additional adjuvant treatment may be required. Some studies have shown that patients can still benefit from adjuvant chemotherapy (AC) despite its t...
Autores principales: | He, Hongbo, Zhang, Peng, Li, Feng, Liu, Donglei, Wu, Kai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830371/ https://www.ncbi.nlm.nih.gov/pubmed/36636082 http://dx.doi.org/10.21037/jgo-22-1008 |
Ejemplares similares
-
Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018) -
Feasibility study of adjuvant chemotherapy with S-1 after curative esophagectomy following neoadjuvant chemotherapy for esophageal cancer
por: Hirahara, Noriyuki, et al.
Publicado: (2022) -
Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022) -
Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
por: Zhang, Baihua, et al.
Publicado: (2023) -
Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study
por: Zhang, Hai, et al.
Publicado: (2023)